The global smart inhalers market size stood at USD 28.62 million in 2019 and is projected to reach USD 445.40 million by 2027, exhibiting a CAGR of 41.1% during the forecast period
The BreatheSuite System – composed of a disposable, battery-powered, portable BreatheSuite MDI add-on device and a mobile application based on behavior change strategies – is designed to work with an MDI by attaching to the top of the canister of the patient’s inhaler. The device and mobile app work together to evaluate and “score” a person’s inhaler technique and usage patterns, storing results in the cloud so the person can track and use this information to improve how they use their inhaler. With consent, this information can also be remotely monitored by the person’s healthcare team to promote customizable care plans. By promoting more effective inhaler use and remote patient monitoring (RPM), BreatheSuite aims to improve quality of care and health outcomes while reducing the economic burden associated with these conditions. Medical costs for chronic COPD were estimated to reach $49 billion in 2020, and the annual economic cost of asthma from 2008-2013 was more than $81.9 billion – with medical costs alone accounting for $50.3 billion.
Get a Sample Copy of the Report at – https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/102705
“We are extremely excited to have obtained FDA clearance, which is a critical step in achieving our vision of improving the lives of respiratory patients worldwide,” said Brett Vokey, Founder and CEO of BreatheSuite. “The COVID-19 pandemic has underscored that now is the time for remote patient monitoring to take a front seat in providing better, more transparent care for all people with asthma or COPD. With FDA clearance, we are poised to become a leader in providing actionable insights to people with asthma or COPD across the United States.”
“By having a real-time way to digitally monitor and provide feedback to patients, we hope to enhance healthcare outcomes,” said Dr. Meshari F. Alwashmi, Chief Scientific Officer, BreatheSuite. “Furthermore, having an objective measure of adherence and technique from each user with asthma and COPD will advance the sphere of knowledge regarding the effectiveness of inhaled medications.”
Key players covered in the global Smart Inhalers Market research report:
- Adherium
- Propeller Health
- Cohero Health Inc.
- GlaxoSmithKline
- AstraZeneca plc
- Novartis AG
- 3M Company
- Teva Pharmaceuticals
- Vectura Group
What are smart inhalers?
Smart inhalers contain sensors that adhere to existing inhalers and record when your medication is appropriated. They are Bluetooth-enabled, so can be dichotomized wirelessly with a smart device like a phone or tablet or with a computer to grant data to be transferred from the smart inhaler automatically.
What are the benefits of smart inhalers?
compensation package range from improving medication adherence to abbreviating hospital admissions, which makes smart inhalers the next influx of respiratory care technology to improve patient outcomes.
- On the Market.
- 'Smart' Benefits.
- Insurance Coverage.
- A Revolution in Lung Disease Treatment.
How much are smart inhalers?
Most smart inhalers are accessible for prices that area between $100 and $500 per device (10).
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Comments
Post a Comment